Kynurenine is the primary metabolite of the kynurenine pathway, which handles ~95% of tryptophan catabolism in the body. While Serotonin gets more attention, the kynurenine pathway is quantitatively dominant—and its downstream metabolites span the range from neuroprotective to neurotoxic.
The pathway's rate-limiting enzymes (IDO1, IDO2, TDO) all require heme iron, creating a direct link between metal biology and neuroimmune signaling.
In the WikiBiome context, the kynurenine pathway is the mechanistic bridge between Metal-Driven Inflammation, metal dyshomeostasis, and neuropsychiatric disease: metal-driven inflammation upregulates IDO1, shunting tryptophan from serotonin to kynurenine, generating neurotoxic quinolinic acid that itself chelates iron and catalyzes Fenton Chemistry—a self-amplifying cycle.
Evidence map6 cited passagesInspect provenance +
Metal-induced inflammation (via NF-kB, TLR4) upregulates IFN-gamma, which induces IDO1, systematically shifting the pathway toward neurotoxic outputs.
QUIN binds iron and forms QUIN-Fe complexes that catalyze Fenton chemistry, generating hydroxyl radicals in neural tissue. This is a direct metal-neuroinflammation link: the kynurenine pathway not only responds to metal-driven inflammation but actively amplifies iron toxicity through its end product.
butyrate and other SCFAs modulate IDO1 expression, linking SCFA-producing commensal health to kynurenine pathway regulation. dysbiosis-driven SCFA depletion removes this brake on IDO1.
3-Indolealdehyde (3-IAld), produced by lactobacillus species, competes with L-kynurenine for AhR binding and tips tryptophan metabolism toward serotonin production via TPH1 induction. Loss of Lactobacillus (common in dysbiosis) removes this competition, allowing kynurenine to dominate AhR signaling.
The kynurenine pathway supports Treg differentiation and immune tolerance via AhR activation. Impairment of this pathway (as observed in long covid and ME/CFS) favors Th17 dominance and autoimmunity.
| Condition | Kynurenine Pathway Alteration | Source | |-----------|------------------------------|--------| | depression | Elevated kynurenine/tryptophan ratio (p=0.008) | | | autism spectrum disorder | Kynurenate significantly depleted (q=0.02) | | | multiple sclerosis | QUIN elevated during relapses; IDO modulated by SCFAs | | | parkinsons disease | Trypt
Contents
1. The Kynurenine Pathway2. Iron Dependency and Metal Connections3. Microbiome Modulation4. Conditions Associated5. Cross-ReferencesThe Kynurenine Pathway#
`` Tryptophan │ ├──[IDO1/IDO2 (heme iron; IFN-gamma-inducible)]──→ Kynurenine │ │ └──[TDO (heme iron; liver, constitutive)]──────────────┘ │ ┌──────────────────────────────┤ │ │ Kynurenic acid (KA) 3-Hydroxykynurenine (3-HK) [neuroprotective] [neurotoxic] [NMDA antagonist] [generates free radicals] │ Quinolinic acid (QUIN) [potent neurotoxin] [NMDA agonist, excitotoxin] [chelates iron → Fenton] ``
Key Metabolites#
| Metabolite | Function | Clinical Relevance |
|---|---|---|
| Kynurenine | AhR (Aryl Hydrocarbon Receptor) ligand; immune modulator | Elevated in inflammation; AhR activation supports Treg differentiation |
| Kynurenic acid (KA) | Neuroprotective; NMDA receptor antagonist | Depleted in ASD (q=0.02); protective against excitotoxicity |
| 3-Hydroxykynurenine (3-HK) | Neurotoxic; generates free radicals | Elevated in neuroinflammation |
| Quinolinic acid (QUIN) | Potent neurotoxin; NMDA agonist; excitotoxin | Elevated in MS relapses; chelates iron and catalyzes Fenton chemistry |
The KA/QUIN Ratio#
The balance between kynurenic acid (neuroprotective) and quinolinic acid (neurotoxic) determines net neurological impact. Inflammation shifts the pathway toward QUIN by upregulating enzymes in the neurotoxic branch.
Iron Dependency and Metal Connections#
IDO1 and TDO Require Heme Iron#
Both rate-limiting enzymes contain heme iron in their active sites. This creates multiple metal-kynurenine interactions. Iron deficiency may impair IDO1/TDO activity, paradoxically reducing kynurenine production.
Iron excess supports IDO1 activity during inflammation, amplifying tryptophan diversion.
Metal-induced inflammation (via NF-kB, TLR4) upregulates IFN-gamma, which induces IDO1, systematically shifting the pathway toward neurotoxic outputs.[1]Novikova 2025 -- Microbiome-Derived Metabolites in Parkinson's Disease (Thesis)Polina Novikova · 2025Open reference 1 ↓
Quinolinic Acid Chelates Iron#
QUIN binds iron and forms QUIN-iron (Fe) complexes that catalyze Fenton chemistry, generating hydroxyl radicals in neural tissue.[1]Novikova 2025 -- Microbiome-Derived Metabolites in Parkinson's Disease (Thesis)Polina Novikova · 2025Open reference 1 ↓ This is a direct metal-neuroinflammation link: the kynurenine pathway not only responds to metal-driven inflammation but actively amplifies iron toxicity through its end product.
Microbiome Modulation#
IDO1 Regulated by SCFAs#
Butyrate and other SCFAs modulate IDO1 expression, linking SCFA-producing commensal health to kynurenine pathway regulation.[2]Multiple Sclerosis: A Story of the Interaction Between Gut Microbiome and Components of the Immune SystemEsraa Mohsen, Hesham Haffez, Sandra Ahmed et al. · 2025Open reference 2 ↓ Dysbiosis-driven SCFA depletion removes this brake on IDO1.
3-IAld Competes with Kynurenine for AhR#
3-Indolealdehyde (3-IAld), produced by Lactobacillus species, competes with L-kynurenine for AhR binding and tips tryptophan metabolism toward serotonin production via TPH1 induction.[3]A microbially produced AhR ligand promotes a Tph1-driven tolerogenic program in multiple sclerosisTeresa Zelante, Giuseppe Paolicelli, Francesca Fallarino et al. · 2024Open reference 3 ↓ Loss of Lactobacillus (common in dysbiosis) removes this competition, allowing kynurenine to dominate AhR signaling.
Immune Tolerance#
The kynurenine pathway supports Treg differentiation and immune tolerance via AhR activation. Impairment of this pathway (as observed in Long COVID and ME/CFS) favors Th17 dominance and autoimmunity.[4]Saito et al 2024 — Metabolomic and Immune Alterations in Long COVID Patients with Chronic Fatigue SyndromeSuguru Saito, Shima Shahbaz, Xian Luo et al. · 2024Open reference 4 ↓
Conditions Associated#
| Condition | Kynurenine Pathway Alteration | Source |
|---|---|---|
| Depression | Elevated kynurenine/tryptophan ratio (p=0.008) | [5]Current Perspectives on Gut Microbiome Dysbiosis and DepressionCapuco A, Urits I, Hasoon J et al. · 2020Open reference 5 ↓ |
| Autism Spectrum Disorder | Kynurenate significantly depleted (q=0.02) | [6]Aziz-Zadeh 2025 — Relationships Between Brain Activity, Tryptophan-Related Gut Metabolites, and Autism SymptomatologyLisa Aziz-Zadeh, Sofronia M. Ringold, Aditya Jayashankar et al. · 2025Open reference 6 ↓ |
| Multiple Sclerosis | QUIN elevated during relapses; IDO modulated by SCFAs | [2]Multiple Sclerosis: A Story of the Interaction Between Gut Microbiome and Components of the Immune SystemEsraa Mohsen, Hesham Haffez, Sandra Ahmed et al. · 2025Open reference 2 ↓ |
| Parkinson's Disease | Tryptophan diverted to kynurenine; QUIN-iron Fenton | [1]Novikova 2025 -- Microbiome-Derived Metabolites in Parkinson's Disease (Thesis)Polina Novikova · 2025Open reference 1 ↓ |
| Long COVID / ME/CFS | Reduced kynurenine products; impaired AhR signaling; Treg failure | [4]Saito et al 2024 — Metabolomic and Immune Alterations in Long COVID Patients with Chronic Fatigue SyndromeSuguru Saito, Shima Shahbaz, Xian Luo et al. · 2024Open reference 4 ↓ |
| Schizophrenia | FMT from SCZ patients altered kyn catabolism in mice | [7]Theleritis 2024 -- Association of gut dysbiosis with first-episode psychosis (Review)Christos Theleritis, Maria-Ioanna Stefanou, Marina Demetriou et al. · 2024Open reference 7 ↓ |
| Cerebral Palsy | Reduced tryptophan pool consistent with kyn/serotonin depletion | [8]Wang 2023 — Plasma amino acid metabolomics identifies diagnostic signature for cerebral palsyDan Wang, Juan Song, Ye Cheng et al. · 2023Open reference 8 ↓ |
| Fibromyalgia | Altered kynurenine pathway in FM-IBS overlap | |
| Postpartum Depression | IDO1 induction during postpartum inflammation |
Cross-References#
- Tryptophan Metabolism—Parent pathway
- Serotonin—Competing pathway for tryptophan
- AhR (Aryl Hydrocarbon Receptor)—Kynurenine as AhR ligand; 3-IAld competition
- Indoles—Third tryptophan metabolic pathway
- Iron—IDO1/TDO heme iron dependency; QUIN-iron (Fe) Fenton
- Fenton Chemistry—QUIN-iron complexes catalyze Fenton reaction
- Oxidative Stress—Downstream of QUIN neurotoxicity
- inflammation—IFN-gamma drives IDO1 induction
- Microbiome-Derived Metabolites—SCFAs modulate IDO1; 3-IAld competes with kynurenine
- Gut-Brain Axis—Kynurenine pathway as neuroimmune signaling axis
References 10
Numbered by first appearance in the article, then reconciled with its declared source list.
- 1
Polina Novikova (2025). Novikova 2025 -- Microbiome-Derived Metabolites in Parkinson's Disease (Thesis). PhD Thesis.
- 2
Esraa Mohsen, Hesham Haffez, Sandra Ahmed et al. (2025). Multiple Sclerosis: A Story of the Interaction Between Gut Microbiome and Components of the Immune System. Molecular Neurobiology.
- 3
Teresa Zelante, Giuseppe Paolicelli, Francesca Fallarino et al. (2024). A microbially produced AhR ligand promotes a Tph1-driven tolerogenic program in multiple sclerosis. Scientific Reports.
- 4
Suguru Saito, Shima Shahbaz, Xian Luo et al. (2024). Saito et al 2024 — Metabolomic and Immune Alterations in Long COVID Patients with Chronic Fatigue Syndrome. Frontiers in Immunology.
- 5
Capuco A, Urits I, Hasoon J et al. (2020). Current Perspectives on Gut Microbiome Dysbiosis and Depression. Advances in Therapy.
- 6
Lisa Aziz-Zadeh, Sofronia M. Ringold, Aditya Jayashankar et al. (2025). Aziz-Zadeh 2025 — Relationships Between Brain Activity, Tryptophan-Related Gut Metabolites, and Autism Symptomatology. Nature Communications.
- 7
Christos Theleritis, Maria-Ioanna Stefanou, Marina Demetriou et al. (2024). Theleritis 2024 -- Association of gut dysbiosis with first-episode psychosis (Review). Molecular Medicine Reports.
- 8
Dan Wang, Juan Song, Ye Cheng et al. (2023). Wang 2023 — Plasma amino acid metabolomics identifies diagnostic signature for cerebral palsy. Frontiers in Molecular Neuroscience.
- 9
Diallo A (2024). Microbiome-Derived Metabolites as Therapeutic Targets in Autoimmune Diseases. Future Publishing House.
- 10
Peng A, et al. (2023). Peng 2023 — Gut Microbiome and Brain Metabolic Remodeling in CP with Epilepsy. Frontiers in Neurology.
Article network
Mentioned here 18
Pages linking here 10
Connect the evidence
Publicly readable discussion by ORCID-authenticated researchers. Questions, interpretation, methods, corrections, and new evidence stay attached to this record.
No discussion yet. Start with a precise question or a source-backed observation.
Activity and accepted changes
Accepted researcher context, editorial status, public discussion, and upstream Git revisions are shown together. Pending, declined, and withdrawn proposals remain private.
- published revision
Backfill inflammation concept links
Karen Pendergrass · +2 −2
Inspect exact Git diff ↗ - published revision
Complete corpus-wide Dysbiosis linking
Karen Pendergrass · +1 −1
Inspect exact Git diff ↗ - published revision
massive wiki expansion: 149 stubs fixed, 100+ new pages, Rule 15 scan, keystone papers
WikiBiome Deploy Bot · +20 −20
Inspect exact Git diff ↗ - published revision
pre-overnight checkpoint 2026-04-18
WikiBiome Deploy Bot · +106 −0
Inspect exact Git diff ↗